Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.63 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1732965 | 0.95 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL1733679 | 0.90 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1 | |
| SCHEMBL1732886 | 0.88 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1 | |
| SCHEMBL1733626 | 0.88 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1 | |
| SCHEMBL1734141 | 0.88 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1 | |
| SCHEMBL1732892 | 0.86 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1 | |
| SCHEMBL1733295 | 0.85 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1 | |
| SCHEMBL1734171 | 0.84 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1 | |
| SCHEMBL1733907 | 0.84 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1 | |
| SCHEMBL1733024 | 0.84 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722903-B2 | Indazole derivatives for the treatment of HSP9O-induced diseases | MERCK PATENT GMBH (DE) | 2014-05-13 | — | — | US | claimed |
| EP-2035391-B1 | INDAZOLE DERIVATIVES FOR TREATING HSP90-INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2011-11-23 | — | — | EP | claimed |
| US-20090197882-A1 | INDAZOLE DERIVATIVES FOR THE TREATMENT OF HSP90-INDUCED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-06 | — | — | US | claimed |
| US-8722903-B2 | Indazole derivatives for the treatment of HSP9O-induced diseases | MERCK PATENT GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2035391-B1 | INDAZOLE DERIVATIVES FOR TREATING HSP90-INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-20090197882-A1 | INDAZOLE DERIVATIVES FOR THE TREATMENT OF HSP90-INDUCED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197882-A1 | INDAZOLE DERIVATIVES FOR THE TREATMENT OF HSP90-INDUCED DISEASES | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.